QuidelOrtho Corporation
0A55.L
$43.50 -0.31%
Exchange: LSE | Sector: Healthcare | Industry: Medical Specialties
Q2 2024
Published: Aug 1, 2024

Earnings Highlights

  • Revenue of $636.30M down 4.3% year-over-year
  • EPS of $-2.20 decreased by 175% from previous year
  • Gross margin of 35.1%
  • Net income of -147.70M
  • ""We are committed to developing innovative diagnostic solutions that we believe will resonate better with market needs, despite the current financial strain."" - CEO
0A55.L
QuidelOrtho Corporation

Executive Summary

QuidelOrtho Corporation faced a challenging second quarter in 2024, reporting a significant net loss of $147.7 million, which marked a staggering 177.63% decline year-over-year compared to previous quarters. This disappointing performance was driven by pronounced revenue declines and escalating operating expenses, primarily attributed to increased research and development costs aimed at innovating within the competitive healthcare diagnostics sector. Management highlighted the difficulties in reversing sales declines, compounded by market dynamics that have shifted demand patterns and heightened operational costs. Investors should remain cautious as the company navigates these turbulent waters, focusing on strategic initiatives that could stabilize and improve its financial position in the coming quarters.

Key Performance Indicators

Revenue
Decreasing
636.30M
QoQ: -14.31% | YoY: -4.33%
Gross Profit
Decreasing
223.50M
35.12% margin
QoQ: -30.16% | YoY: -24.60%
Operating Income
Decreasing
-30.30M
QoQ: -175.56% | YoY: -12.64%
Net Income
Decreasing
-147.70M
QoQ: -2 210.00% | YoY: -177.63%
EPS
Decreasing
-2.20
QoQ: -2 300.00% | YoY: -175.00%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2025 613.90 -3.77 -3.5% View
Q1 2025 692.80 -0.19 -6.7% View
Q4 2024 707.80 -2.28 -0.3% View
Q3 2024 727.10 -0.30 -2.3% View
Q2 2024 636.30 -2.20 -4.3% View